Unlike other subtypes, such as ER/PR positive BC that benefit from endocrine therapies or HER2 positive BC that can be treated by HER2-targeting antibody or antibody-conjugated drugs, TNBC has fewer subtype-specific treatment options. This evidence concerns the gene PGR and breast cancer.